Evidence map›Paper›PMID 30596734›Full record

Trial reportPloS one2018

Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study.

Ye Minn Htun, Tin Mi Mi Khaing, Nay Myo Aung, Yin Yin, Zaw Myint, Si Thu Aung, Ngamphol Soonthornworasiri, Udomsak Silachamroon, Yuthichai Kasetjaroen, Jaranit Kaewkungwal

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Efficacy and safety profile of 2Pakistan journal of medical sciences · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ye Minn HtunDefence Services Medical School, Hmawbi, Yangon, Myanmar.
Tin Mi Mi KhaingRegional Tuberculosis Center, Yangon, Myanmar.
Nay Myo AungDepartment of Chest Medicine, Defence Services Medical Academy, Yangon, Myanmar.
Yin YinRegional Tuberculosis Center, Yangon, Myanmar.
Zaw MyintRegional Tuberculosis Center, Yangon, Myanmar.
Si Thu AungNational Tuberculosis Programme, Ministry of Health and Sports, Nay Pyi Taw, Myanmar.
Ngamphol SoonthornworasiriDepartment of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Udomsak SilachamroonDepartment of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Yuthichai KasetjaroenTuberculosis Program of the Bureau of Tuberculosis, Bangkok, Thailand.
Jaranit KaewkungwalDepartment of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.ORCID 0000-0001-7916-8460
Myanmar Oxford Clinical Research Unit · MMMahidol University · THMinistry of Health and Sports · MM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyanmar faces a health security threat, with an increasing number of multidrug-resistant tuberculosis (MDR-TB) cases. Long delays in the initiation of treatment are a barrier to MDR-TB control.

objectivesThe main objectives of this study were (1) to identify the determinants of delay in treatment initiation after MDR-TB diagnosis, and (2) to explore the effects of treatment delay on disease infectivity, severity, treatment adherence, and treatment outcomes.

methodsThis retrospective study reviewed 330 MDR-TB treatment cards for patients enrolled for treatment at Yangon Regional Tuberculosis Centre, in 2014.

resultsMedian treatment delay was 105 days, interquartile range (IQR) 106 (61-167) days; (51.5%) of patients experienced a long treatment delay (≥ 105 days). Regarding the determinants of treatment delay, this study identified important patient-healthcare system interaction factors. Significant risk factors of long treatment delay included female sex, age > 30 years, and prior contact with patients with MDR-TB. Patients with long treatment delays were significantly different from those with short delays, in terms of having high sputum smear grade, resistance to more than two main drugs (isoniazid and rifampicin), and long culture conversion time. In this study, delay in the initiation of treatment was associated with poor treatment outcome, but this was not statistically significant after adjusting for other risk factors. Median treatment-delay times were longer among patients with poor outcomes (144 days) than those with successful outcomes (102 days).

conclusionsPost-diagnosis delays in the initiation of treatment among MDR-TB patients were significantly long. The study results showed that inadequate MDR-TB treatment initiation center, centralization of treatment initiation, limitation of human resources, were health-system factors delaying timely treatment initiation and implementation of an effective TB-control program. Our findings highlight the need for immediate interventions to reduce treatment delay and improve treatment outcomes, including scaling up diagnostic capacity with Xpert MTB/RIF at township level, expansion of decentralized MDR-TB treatment initiation centers, ensuring a productive health workforce comprising trained health personnel, and providing health education and treatment-adherence counseling to patients and family members.

Indexed as

Patient Education as TopicSeverity of Illness IndexTreatment Adherence and ComplianceTuberculosis, Multidrug-ResistantAdolescentAdultAgedFemaleHumansMaleMiddle AgedMyanmarRetrospective StudiesRisk FactorsTime Factors

Identifiers

PMID30596734
PMCPMC6312206
OpenAlexW2906875615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.